Alliance Pharma Regulatory News (APH)

22 Feb 2008 12:23

Alliance Pharma PLC22 February 2008 For Immediate Release 21 February 2008 ALLIANCE PHARMA PLC TR - 1: NOTIFICATION OF MAJOR INTERESTS IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Alliance Pharma plc 2. Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights 3. Full name of person(s) subject to the notification obligation: Aviva plc & its subsidiaries 4. Full name of shareholder(s) (if different from 3.) Registered Holder: CUIM Nominee Limited 2,700,000* * denotes direct interest BNP Paribas - London 4,450,000 Chase Nominees Limited 11,025,755 5. Date of the transaction and date on which the threshold is crossed or reached: 20 February 2008 6. Date on which issuer notified: 21 February 2008 7. Threshold(s) that is/are crossed or reached: 10% to 11% Change at Combined Interest Level 8. Notified details: 3.11 A: Voting rights attached to shares +--------------+----------------------+--------------------------------------------------+|Class/type of |Situation previous to |Resulting situation after the triggering ||shares |the Triggering |transaction || |transaction | ||if possible +----------+-----------+---------+----------------------+-----------------+|using the ISIN|Number of |Number of |Number of|Number of voting |% of voting ||CODE |Shares |Voting |shares |rights |rights || | |Rights +---------+----------+-----------+--------+--------+| | | |Direct |Direct |Indirect |Direct |Indirect|+--------------+----------+-----------+---------+----------+-----------+--------+--------+|GB0031030819 |17,175,755|17,175,755 |2,700,000|2,700,000 |15,475,755 |1.67% |9.55% |+--------------+----------+-----------+---------+----------+-----------+--------+--------+ Total (A+B) Number of voting rights % of voting rights18,175,755 11.22% 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable n/a Proxy Voting: 10. Name of the proxy holder: n/a 11. Number of voting rights proxy holder will cease to hold: n/a 12. Date on which proxy holder will cease to hold voting rights: n/a 13. Additional information: Figures are based on a total number of voting rights of 162,061,774 For further information: Alliance Pharma plc + 44 (0) 1249 466966 John Dawson, Chief ExecutiveRichard Wright, Finance Directorwww.alliancepharma.co.uk Buchanan Communications + 44 (0) 20 7466 5000 Mark Court / Rebecca Skye Dietrich Numis Securities + 44 (0) 20 7260 1000David Poutney / Michael Meade This information is provided by RNS The company news service from the London Stock Exchange